Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
==================================================================================================================================================================================================

* Colt Egelston
* Weihua Guo
* Susan Yost
* Jin Sun Lee
* David Rose
* Christian Avalos
* Jian Ye
* Paul Frankel
* Daniel Schmolze
* James Waisman
* Peter Lee
* Yuan Yuan